Diversified Holdings · Industrial Conglomerates
| Year | Revenue | Net profit | EPS |
|---|---|---|---|
| 2026 | Rs 65.9B | Rs 5.0B | 1.55 |
| 2025 | Rs 59.3B | Rs 5.9B | 2.15 |
| 2024 | Rs 55.5B | Rs 6.0B | 9.09 |
| 2023 | Rs 51.9B | Rs 3.6B | 4.67 |
| 2022 | Rs 32.2B | Rs 5.0B | 6.06 |
| 2021 | Rs 24.3B | Rs 2.5B | 3.39 |
| 2020 | Rs 20.8B | Rs 1.8B | 7.67 |
Sunshine Holdings PLC is a diversified Sri Lankan conglomerate operating across healthcare, consumer goods and agribusiness, delivering products and services for consumers, institutions and industries in Sri Lanka and beyond. The Group’s portfolio spans pharmaceuticals and medical devices, distribution and retail, local pharmaceutical manufacturing, branded consumer goods including tea and confectionery, and primary agri‑commodities such as palm oil and dairy. The Healthcare businesses encompass prescription and branded generics, medical devices, wholesale and retail distribution (including Healthguard distribution and retail operations) and local pharmaceutical manufacturing, supported by long‑term partnerships with multinational principals such as Zydus Lifesciences, Novo Nordisk, Cadila, Glenmark, Hilton Pharma and Galderma. The Consumer segment comprises branded consumer products, tea and confectionery and export‑oriented consumer initiatives, while the Agri business covers palm oil and dairy operations and is being repositioned toward higher‑value, export‑oriented opportunities (including the acquisition of Joint Agri Products Ceylon (Pvt) Ltd). Group level strategic investments and functions coordinate capital allocation, governance and cross‑business capabilities.
No AI research report for Sunshine Holdings PLC yet. Generate one from everything we track: prices, valuation, news sentiment, financials and corporate actions.
Generate an analysis →No scored news in the last 30 days.
Sunshine Holdings PLC and India’s Zydus Lifesciences will form a $20m joint venture, Zydus Sunshine Lifesciences Ltd., to build a pharmaceutical manufacturing plant on nearly four acres in BOI Horana to boost local drug production and reduce imports.
Sunshine Holdings, in a JV with Zydus Lifesciences (Zydus Sunshine Lifesciences Pvt Ltd), will build a US$20 million pharmaceutical manufacturing plant on nearly four acres in the BOI zone at Horana to supply Sri Lanka's retail market. The project will focus on local production, technology transfer and job creation under NMRA oversight.
Sunshine Holdings PLC and Zydus Lifesciences formed Zydus Sunshine Lifesciences Pvt Ltd with an investment commitment of over USD 20 million to build a pharmaceutical manufacturing facility at the BOI Horana to boost local production and reduce import reliance.
Sunshine Holdings reported consolidated FY26 revenue of Rs.65.9 billion, up 11.2% YoY. PAT was Rs.5.0 billion (down 2.5% YoY) as NMRA pricing cuts weighed on healthcare margins, and the group acquired a majority stake in Joint Agri Products Ceylon Ltd to bolster exports.
Sunshine Holdings (SUN) reported FY26 consolidated revenue of LKR 65.9bn, up 11.2% YoY, while PAT fell 2.5% to LKR 5.0bn and EBIT margins eased amid healthcare pricing pressure. The Group cited NMRA pricing cuts, acquired a majority stake in JAPC, and saw Watawala's palm oil revenue rise 23.6%.